Zhifei Actively Participates in China-Uzbekistan Vaccine Cooperation

Chinese President Xi Jinping paid a state visit to Uzbekistan during 14th-15th Sep. In time of the visit, the two heads of state said that bearing in mind the long-term development of China-Uzbekistan relations and the future welfare of their people, the two countries will expand mutually beneficial cooperation, cement their friendship and partnership, and implement the vision of a community with a shared future at the bilateral level. The Chinese side will continue to carry out healthcare, vaccine and pharmaceutical cooperation with Uzbekistan, and support the building of vaccine production centers in Uzbekistan, Xi said. Mirziyoyev said Uzbekistan appreciates China's valuable support for its national development and fight against COVID-19. ¹

Since 2020, in the face of the severe epidemic situation, Zhifei has joined hands with the Institute of Microbiology, Chinese Academy of Sciences and The Alliance of International Science Organizations (ANSO) to actively carry out vaccine cooperation with Uzbekistan, implementing One Belt, One Road initiative with practical actions to protect the health of people in both countries.

In November 2020, the overseas phase III clinical trial of the Recombinant COVID-19 Vaccine (CHO Cell) was officially launched in Uzbekistan, and Uzbekistan became the first country to cooperate with Zhifei in the clinical trial of the vaccine, and a total of about 7,000 Uzbek volunteers participated in the phase III clinical trial of the vaccine, and the trial results showed that the vaccine is with good safety and efficacy.

In March 2021, the Recombinant COVID-19 Vaccine (CHO Cell) was approved for marketing in Uzbekistan, becoming the first recombinant protein COVID-19 vaccine to be marketed in the world. In the same month, the first batch of 1 million doses of the vaccine arrived in Tashkent, the capital of Uzbekistan, effectively mitigating the spread of the epidemic there.

On August 5th, 2021, the Foreign Affairs Office of Anhui Provincial People’s Government hosted the online signing ceremony for the cooperative production of the Recombinant COVID-19 Vaccine (CHO Cell) between Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd and JURABEK LABORATORIES JV LLC. The signing ceremony was attended by Abdurakhmonov, Minister of the Ministry of Innovative Development of Uzbekistan, Zhang Qingdong, Minister-Counsellor of the Chinese Embassy in Uzbekistan, Yong Chenghan, Director of Anhui Foreign Affairs Office, and relevant officials from Pharmaceutical Industry Development Agency of the Ministry of Health of Uzbekistan and the Chinese Embassy in Uzbekistan.

On October 1st, 2021, the first batch of the Recombinant COVID-19 Vaccine (CHO Cell) produced locally in Uzbekistan was launched from JURABEK LABORATORIES JV LLC. By the end of 2021, the Recombinant COVID-19 Vaccine (CHO Cell) accounted for about 70% of the total number of COVID-19 vaccines administered in Uzbekistan.

(Photo shows the Uzbek pharmaceutical company JURABEK LABORATORIES JV LLC staff working on the production line of the Recombinant COVID-19 Vaccine (CHO Cell) jointly developed by the Institute of Microbiology, Chinese Academy of Sciences and Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd. Source: Xinhua)

Currently, Zhifei has established in-depth cooperation with the Ministry of Innovative Development and the Pharmaceutical Industry Development Agency of Uzbekistan, fully integrated the superior resources of both sides, jointly promoted the use of the company's recombinant protein COVID-19 vaccine in Central Asia and CIS countries, actively responded to One Belt, One Road cooperation initiative, took the social responsibility of Chinese vaccine enterprises, and contributed to the global epidemic prevention.

References
1.http://www.news.cn/2022-09/15/c_1129005699.htm